No gold standard anticholinergic burden scale was identified. Scales with broader drug coverage and accounting for individual variability appeared more clinically relevant. This review highlights the need for a clinically accessible, universal scoring system to better address the risks associated with anticholinergic polypharmacy.
Vennard et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: